Two Sigma Investments’s Liminatus Pharma LIMN Stock Holding History

Two Sigma Investments’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,284	Closed	-$21.5K	–	5021
2025 Q4	$21.5K	Buy	+35,284	New	+$39.2K	﹤0.01%	3992

Other funds holding LIMN

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPIM

Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's LIMN Position: Q1 2026 in Review

Two Sigma Investments sold out of Liminatus Pharma (LIMN) in Q1 2026, closing a stake of 35,284 shares — an estimated $21.5K sold.

Two Sigma Investments first reported a position in LIMN in Q4 2025 and held it in 1 quarter. The position peaked at $21.5K in Q4 2025. 15 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

Two Sigma Investments reported no remaining Liminatus Pharma position as of Q1 2026 after selling out during the quarter.
Two Sigma Investments sold 35,284 Liminatus Pharma shares in Q1 2026, an estimated $21.5K.
Two Sigma Investments first reported a position in Liminatus Pharma in Q4 2025 and held it in 1 quarter.
Two Sigma Investments's Liminatus Pharma position peaked at $21.5K in Q4 2025.
15 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.